FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma

Haematologica

Volumn 93, Issue 8, 2008, Pages 1269-1271

  Salaun, Pierre Yves ^a   Gastinne, Thomas ^a   Frampas, Eric ^a   Bodet Milin, Caroline ^a   Moreau, Philippe ^a   Bodéré Kraeber, Françoise ^a,b  

^a HÔTEL DIEU   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LETTER; MALE; PLASMACYTOMA; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SOFT TISSUE; TREATMENT RESPONSE; TUMOR BIOPSY;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; PLASMACYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48749110375     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12654     Document Type: Letter

References (10)

1. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999;13:1249-57.
2. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993;11:1311-5.
3. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006;81:693-703.
4. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002;94:1532-7.
5. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
6. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037-44.
7. 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007;92:50-5.
8. Schirrmeister H, Bommer M, Buck AK, Muller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using FDG-PET. Eur J Haematol Med 2002;29:361-6.
9. Durie GM, Waxman AD, D'Agnolo A, Williams CM. Whole body18F-FDG-PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.
10. Nanni C, Zamagni E, Farsad M, Castelluci P, Tosi P, Cangini D, et al. Role of F18-FDG PET/Ct in the assessment of bone involvement in newly diagnosed multiple myeloma : preliminary results. Eur J Nucl Med Mol Imaging 2006;33:525-31.